One of the only
solutions for victims of stroke and brain injury
Point
Roberts WA, NEW YORK, NY -- June 18, 2015 - Investorideas.com, a global news
source covering leading sectors including biotech and medical technology issues
a video alert for Vycor Medical, Inc (OTCQB:VYCO) featuring its NovaVision
Vision Restoration Therapy. The company’s proprietary Visual Restoration
Therapy® (VRT) platform is clinically supported to improve lost vision
resulting from Stroke, Traumatic Brain Injury (TBI), or other acquired brain
injuries.
See the video on
YouTube.com - NovaVision Vision Restoration Therapy
Read this release in
full at http://www.investorideas.com/CO/VYCO/news/2015/06181.asp
About Vycor Medical,
Inc.
With
corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (“Vycor”) is a
publicly traded company (OTCQB—VYCO) dedicated to providing the medical
community with innovative and superior surgical and therapeutic solutions and
has a growing portfolio of FDA cleared medical solutions that are changing and
improving lives every day. The Company operates two business units: Vycor
Medical and NovaVision, both of which adopt a minimally or non-invasive
approach. Both technologies have exceptional sales growth potential, address
large potential markets, have the requisite regulatory approvals and are
commercialized and generating revenue.
Vycor
Medical’s ViewSite™ Surgical Access Systems (VBAS) is a suite of clear
cylindrical minimally invasive disposable devices that hold the potential for
speedier, safer and more economical brain surgeries and a quicker patient
discharge. VBAS is designed to optimize neurosurgical site access, reduce
patient risk, accelerate recovery and add tangible value to the professional
medical community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k)
clearance for brain and spine surgeries and full regulatory approvals for brain
in Australia, Brazil, Canada, China, Europe (EU – Class III), Korea and Japan
and is seeking or has partial regulatory approvals in India, Russia, Taiwan and
Vietnam. For an overview of Vycor Medical’s VBAS see VBAS Video.
NovaVision
develops and provides science-driven neurostimulation therapy and other medical
technologies that help improve and partially restore sight in patients with
neurological vision impairments. The
company’s proprietary Visual Restoration Therapy® (VRT) platform is clinically
supported to improve lost vision resulting from Stroke, Traumatic Brain Injury
(TBI), or other acquired brain injuries. VRT is the only FDA 510K cleared
medical device in the U.S. aimed at the restoration of vision for
neurologically induced vision loss and can be prescribed by any physician. VRT also has CE Marking for the EU.
NovaVision also provides Neuro Eye Therapy (NeET) in the EU, aimed at
increasing visual sensitivity deep within the field defect.
The
Company has also developed NeuroEyeCoach™, a therapy which is highly complementary
to VRT™. The two therapies
address different visual disabilities each of which results from
neurologically-induced vision loss – a loss of visual field as well as
difficulty with eye movement, affecting the ability to integrate visual
information. VRT provides partial restoration of the patient’s lost visual
field; NeuroEyeCoach™ is designed to increase the efficiency of eye movement
and re-train the patients’ ability to integrate visual information between the
left and right hand side. For an overview
of NovaVision see NovaVision
Video.
For
the latest information on the company, including media and other coverage, and
to learn more, please go online at www.vycormedical.com,
www.vycorvbas.com or www.novavision.com.
InvestorIdeas.com newswire is a global investor
news source covering leading sectors including medical technology and biotech.
Sign up for free news alerts at Investorideas.com
Become an
Investorideas.com Member and access our online stock directories listing
thousands of publicly traded stocks in leading sectors
Disclaimer/ Disclosure: The Investorideas.com
newswire is a third party publisher of news and research as well as creates
original content as a news source. Original content created by investorideas is
protected by copyright laws other than syndication rights. Investorideas is a
news source on Google news syndication partners. Our site does not make
recommendations for purchases or sale of stocks or products. Nothing on our
sites should be construed as an offer or solicitation to buy or sell products
or securities. All investment involves risk and possible loss of investment.
This site is currently compensated by featured companies, news submissions,
content marketing and online advertising. Contact each company directly for
press release questions. Disclosure is posted on each release if required but
otherwise the news was not compensated for and is published for the sole
interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
(VYCO): June 2, 2015 – The company has retained Investor Ideas for PR, media
and news distribution: Five thousand per month, one month with option to renew.
BC Residents and Investor Disclaimer :
Effective September 15 2008 - all BC investors should review all OTC and Pink
sheet listed companies for adherence in new disclosure filings and filing
appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
. Global investors must adhere to regulations of each country.
Contact Investorideas.com
800 665 0411
No comments:
Post a Comment